Symposia 9 - Perplexed By Paris? We Have Answers! Updates on The Paris System for Reporting Urinary Cytology
The Paris System for Reporting Urinary Cytology (TPS) was a revolutionary approach to urine as a screening and diagnostic tool for bladder cancer when it was published in 2016. It provided a standard classification and terminology system with well-defined diagnostic criteria that were widely accepted and adopted. Most of the criteria were based on previous studies and experience of the authors, but many questions were raised for future discovery. Six years later and following numerous post-TPS publications, the second edition of TPS, released in January 2022, has now addressed many of those questions, but some remain. The 7 panelists are major contributors to TPS and will respond to the most compelling issues in need of clarification. Time will be provided for Q&A at the end of the session.
This educational activity is designed for pathologists, cytopathologists, cytotechnologists, students and other members of the cytopathology community.
- Understand the morphologic differences among diagnostic categories of The Paris System for Reporting Urinary Cytology
- Appreciate the genetic bases for classifying some neoplasms as non-malignant
- Recognize the criteria to classify cells as non-neoplastic and negative for HGUC
- Learn the tools needed to establish the histologic origin of an abnormal cell population
Tatjana Antic, MD
Fadi Brimo, MD, FRCPC
Tarik M. Elsheikh, MD
Daniel I. Kurtycz, MD
Dorothy Rosenthal, MD
Momin T. Siddiqui, MD
Christopher VandenBussche, MD, PhD
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
The faculty, committee members, Executive Board and staff who are in position to control the content of this activity are required to disclose to the ASC and to learners any financial relationships that have occurred within the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ASC has reviewed the disclosures and mitigated all relevant financial relationships.
The following individuals have reported financial relationships:
Michael Berry, SCT(ASCP)MBCM: Stockholder-Hologic
Oscar Lin, MD, PhD: Consultant – Hologic and Jansen
Liron Pantanowitz, MD: Consultant – Hamamatsu, Advisory Board for Ibex
Martha B. Pitman, MD, FIAC: Consultant – Adenocyte, LLC
Donna K. Russell, MEd, CT(ASCP), HT(ASCP): Advisory Board – Hologic Scientific
Christopher J. VandenBussche, MD, PhD: Ad hoc advisory board panel and Consultant – Roche
Paul VanderLaan, MD, PhD: Consultant – Gala Therapeutics
The following individuals have reported no relevant financial relationships:
Susan A. Alperstein, MS, CT(ASCP), Kristen A. Atkins, MD, Zubair, Baloch, MD, PhD, Guliz A. Barkan, MD, Christine N. Booth, MD, Leigh Ann Cahill, BS, CT(ASCP)CMIAC, Barbara A. Centeno, MD, Deborah J. Chute, MD, Amy C. Clayton, MD, Jacqueline M. Cuda, BS, SCT(ASCP), Fang Fan, MD, PhD, Kara L. Hansing, MEd, SCT(ASCP)CM, Aparna M Mahajan MD, Sara E. Monaco, MD, Michiya Nishino MD, PhD, N. Paul Ohori MD, Lynnette S. Pineault, MBA, SCT(ASCP), Sinchita Roy-Chowdhuri, MD, PhD, Momin T. Siddiqui, MD, FIAC, Z. Laura Tabatabai, MD, Sana O. Tabbara, MD, Michael J. Thrall, MD, Dena M. Tonkovich, BS, CT(ASCP), Dawn L. Underwood, MS, CT(ASCP), Vivian L. Weiss, MD, PhD, Teresa Wood, MPH, BA, CT(ASCP), Lisa Zhang, MD, Tatjana Antic, MD, Fadi Brimo, MD, FRCPC, Tarik M. Elsheikh, MD, Daniel I. Kurtycz, MD, Dorothy Rosenthal, MD
The ASC staff associated with the development of content for this activity reported no relevant financial relationships.
Continuing Medical Education (CME) Statement
The American Society of Cytopathology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society of Cytopathology designates this enduring educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
American Board of Pathology Maintenance of Certification (CC)
This product can help fulfill the CME requirements mandated by the American Board of Pathology Continuing Certification (CC) process. Earn up to 2.0 Credit Hours.
Continuing Medical Laboratory Education (CMLE)
The ASC designates this activity for a maximum of 2.0 Continuing Medical Laboratory Education (CMLE) credit hours for non-physicians. The CMLE credit hours meet the continuing education requirements for the ASCP Board of Registry Certification Maintenance Program. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Cytotechnologists with Licenses in Florida and California
This program is approved for 2 continuing education credits in the States of Florida and California. The credit on each link is good for three years from the live presentation date.
- 2.00 AMA PRA Category 1 Credit™
- 2.00 California Credits
- 2.00 CMLE
- 2.00 Florida Credits
- 2.00 Participant